Used to control the growth of E. coli O157:H7; extracellular matrix (ECMl); to control or prevent the infection or colonization of processed and unprocessed food products
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberIntralytixIntralytixIntralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Publication Number
US-7635584-B2
Publication Date
2009-12-22
Expiration Date
Abstract
The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.
Core Innovation
The invention relates to an isolated bacteriophage of strain ECML-4 deposited under ATCC accession No. PTA-7948, having lytic activity against E. coli O157:H7 strains and variants thereof. The variants have the same phenotypic characteristics as the bacteriophage and have the same lytic activity against E. coli O157:H7 strains as the bacteriophage.
The disclosure further provides compositions, progeny, and derivatives based on the ECML-4 bacteriophage for controlling growth or colonization of targeted bacteria. The document describes lytic specificity for E. coli O157:H7 and outlines use of recombinant phage reporters and phage-lysis-driven ATP/AK measurements to identify viable E. coli O157:H7 in samples from food, food-processing environments, and animals (including humans).
Supporting data are described showing lysis of tested E. coli O157:H7 strains while showing substantially different lysis behavior against non-O157:H7 E. coli and against unrelated bacterial species, including S. aureus, L. monocytogenes, Salmonella spp., and P. aeruginosa. The document also discusses derivative applications including recombinant/reporter approaches and phage-lysis-linked measurements to detect viable targeted bacteria.
Claims Coverage
The available independent claim provides two main inventive features: the specific isolated ECML-4 bacteriophage deposited under ATCC PTA-7948, and its lytic activity with defined phenotypic and lytic equivalence for E. coli O157:H7 variants.
Isolated ECML-4 bacteriophage deposited under ATCC PTA-7948
An isolated bacteriophage of strain ECML-4 deposited under ATCC accession No. PTA-7948.
Lytic activity against E. coli O157:H7 variants with same phenotypic characteristics and lytic activity
Lytic activity against E. coli O157:H7 strains and variants thereof, wherein the variants have the same phenotypic characteristics as the bacteriophage and the variants have the same lytic activity against E. coli O157:H7 strains as the bacteriophage.
The claim coverage centers on the isolated ECML-4 bacteriophage deposited as ATCC PTA-7948 with lytic activity against E. coli O157:H7 strains, including variants having the same phenotypic characteristics and the same lytic activity.
Stated Advantages
Provides lytic activity against E. coli O157:H7 strains and variants with defined phenotypic characteristics and equivalent lytic activity.
Demonstrates lysis of a substantial proportion of tested E. coli O157:H7 strains while showing limited or no lysis against non-O157:H7 E. coli and unrelated bacterial species.
Enables detection of viable E. coli O157:H7 using recombinant phage reporters and phage-lysis-driven ATP/AK measurements.
Documented Applications
Controlling growth or colonization of targeted bacteria on raw or processed foods.
Controlling growth or colonization of targeted bacteria in food-processing equipment and environments.
Controlling growth or colonization of targeted bacteria in animals, including humans.
Detecting viable E. coli O157:H7 in food, environment, and clinical samples using recombinant phage reporters and phage-lysis-driven ATP/AK measurements.
Interested in licensing this patent?